# Definitive Concurrent Chemoradiotherapy With Docetaxel Plus Cisplatin Versus 5-fluorouracil Plus Cisplatin in Patients With Esophageal Squamous Cell Carcinoma

> **NCT02969473** · PHASE2 · UNKNOWN · sponsor: **Zhu Yujia** · enrollment: 120 (estimated)

## Conditions studied

- Esophageal Neoplasm
- Chemoradiation

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Fluorouracil

## Key facts

- **NCT ID:** NCT02969473
- **Lead sponsor:** Zhu Yujia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-10
- **Primary completion:** 2016-05
- **Final completion:** 2017-05
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2016-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02969473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02969473, "Definitive Concurrent Chemoradiotherapy With Docetaxel Plus Cisplatin Versus 5-fluorouracil Plus Cisplatin in Patients With Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02969473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*